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Abstract 
Background: Electroencephalography at hospital presentation may offer important insights regarding prognosis 
that can inform understanding of cerebral malaria (CM) pathophysiology and potentially guide patient selection and 
risk stratification for future clinical trials. Electroencephalogram (EEG) findings in children with CM in Uganda and 
Malawi were compared and associations between admission EEG findings and outcome across this diverse popula‑
tion were assessed. Demographic, clinical and admission EEG data from Ugandan and Malawian children admitted 
from 2009 to 2012 with CM were gathered, and survivors assessed for neurological abnormalities at discharge.
Results: 281 children were enrolled (Uganda n = 122, Malawi n = 159). The Malawian population was comprised 
only of retinopathy positive children (versus 72.5% retinopathy positive in Uganda) and were older (4.2 versus 
3.7 years; p = 0.046), had a higher HIV prevalence (9.0 versus 2.8%; p = 0.042), and worse hyperlactataemia (7.4 
versus 5.2 mmol/L; p < 0.001) on admission compared to the Ugandan children. EEG findings differed between the 
two groups in terms of average voltage and frequencies, reactivity, asymmetry, and the presence/absence of sleep 
architecture. In univariate analyses pooling EEG and outcomes data for both sites, higher average and maximum 
voltages, faster dominant frequencies, and retained reactivity were associated with survival (all p < 0.05). Focal slowing 
was associated with death (OR 2.93; 95% CI 1.77–7.30) and a lower average voltage was associated with neurological 
morbidity in survivors (p = 0.0032).
Conclusions: Despite substantial demographic and clinical heterogeneity between subjects in Malawi and Uganda 
as well as different EEG readers at each site, EEG findings on admission predicted mortality and morbidity. For CM 
clinical trials aimed at decreasing mortality or morbidity, EEG may be valuable for risk stratification and/or subject 
selection.
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Background
Cerebral malaria (CM) is defined as an otherwise unex-
plained coma in a patient with malaria parasitaemia [1]. 
Despite improvements in anti-malarial treatment regi-
mens, the mortality rate in tertiary care centres remains 
15–25% and approximately one-third of survivors are 
left with neurological sequelae at hospital discharge 
including developmental or behavioural abnormalities, 
and epilepsy [2, 3]. Single-site studies have suggested 
that admission electroencephalogram (EEG) may offer 
important insights into both prognosis [4, 5] and the 
pathophysiology of CM [2]. Several phase  II and III 
clinical trials aimed at improving survival and neu-
rologic outcomes from CM are ongoing or have been 
recently completed [6–9]. Future phase III clinical tri-
als could potentially benefit from validation of a non-
invasive biomarker that allows identification of children 
at high risk of death. Such a marker might allow for 
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subject enrichment during enrollment or stratification 
of collected data.
EEG is not routinely available across Africa. Previously 
published single-site case series have reported a num-
ber of abnormalities in the EEGs of children with CM 
including diffuse slowing, atypical sleep elements (spin-
dles and vertex waves), and epileptiform activity [5, 10, 
11]. In a case series of 65 Kenyan children with CM, a 
slower background frequency was significantly associ-
ated with an increased risk of death [5]. Burst-suppres-
sion was found in a higher proportion of children who 
died compared to those who lived, but the numbers of 
children with burst-suppression was small and the differ-
ences in proportions between outcome groups were not 
statistically significantly different. A report from Malawi 
identified a lack of variability and reactivity to painful 
stimulation as a risk factor for mortality [12]. A recently 
published study of acute magnetic resonance imaging 
and EEG findings in 168 Malawian children with CM 
determined that a slower background frequency was sig-
nificantly associated with increased mortality risk [4]. No 
multi-site studies of EEG in CM have been published.
The epidemiology of CM is rapidly evolving due to cli-
mate change and successful control programs resulting 
in some regions with decreased disease burden, coun-
tered by other regions where incidence is constant or 
increasing [1]. Definitive clinical trials aimed at decreas-
ing malaria morbidity and mortality will likely require 
multiple study sites both to assure access to adequate 
numbers of eligible children as well as improve the gen-
eralizability of results. To explore the potential value of 
EEG for subject selection or stratification in future clini-
cal trials, admission EEG factors were compared between 
the two study sites, and the associations of these factors 
with death and neurodisability in Malawian and Ugan-
dan children determined. This study’s goal was to identify 
EEG factors associated with death or neurological dis-
ability that could potentially inform future clinical trials. 
Identification of EEG changes associated with mortality 
and morbidity that might allow further insight into the 
underlying pathophysiology of death and disability in 
children with CM were assessed.
Methods
Clinical and admission EEG data in consecutively admit-
ted children with CM from Uganda and Malawi were 
gathered. Mulago Hospital is a large (1600 bed) Ugandan 
public tertiary care facility located in the country’s capi-
tal, Kampala. Queen Elizabeth Central Hospital (QECH) 
is the largest public health care facility in Malawi and 
located in the country’s commercial capital of Blantyre. 
Both hospitals are home to independent long-stand-
ing studies of severe malaria pathogenesis and natural 
history. Children 6  months to 15  years old, admitted to 
either Mulago or QECH with a clinical diagnosis of CM 
(Blantyre coma score ≤ 2, Plasmodium falciparum on 
peripheral blood smear, and no other known aetiology of 
coma) between December 2008 and January 2012 were 
eligible for inclusion. All children included in this sub-
study were recruited for comprehensive projects studying 
CM pathogenesis and clinical epidemiology.
Nurse to patient ratios were high in both countries (one 
nurse to two patients or occasionally 1:1)—substantially 
higher than is the standard of routine care. In Malawi, 
children were hospitalized on a paediatric research ward 
dedicated to the study of children in coma, while in 
Uganda they were admitted to the high acuity ward (pae-
diatric intensive care unit) with dedicated study nurses.
EEGs were recorded within 12  h of admission at 
both sites. All children were comatose (Blantyre Coma 
Score ≤ 2) at the time of recording. Malawi used a Cee-
graph digital machine (BioLogic/Natus, Pleasanton, 
California) and Uganda an XLTEC 32 channel machine 
(Natus Medical Corporation, Pleasanton, California). 
EEG technicians used the international 10–20 system 
for electrode placement. Recording duration was 30 min 
or more, unless the patient became medically unstable 
or was otherwise unable to tolerate the procedure. EEG 
interpretations used for patient care were performed 
during hospitalization by study and non-study personnel 
to assess for non-convulsive status epilepticus or elec-
trographic seizures. Research interpretations used for 
this study were performed after hospital discharge by a 
paediatric neurologist (DP, Uganda) or an epileptolo-
gist (GB and PK, Malawi) using Persyst Insight II (Per-
syst corporation, Prescott, Arizona). Interpreters were 
blinded to the child’s outcome. Interpretations were 
scored on a standardized form with predetermined defi-
nitions for each finding. These included: a determination 
of average background frequency; average and maximal 
voltages (excluding vertex sharp waves); the absence or 
presence of spontaneous EEG variability; the absence or 
presence of sleep spindles; the absence or presence of 
vertex waves; a quantitation of the proportion of epochs 
with sleep spindles (0, 1–25%, 26–50%, 51–75%, > 75%); 
identification and characterization of epileptiform activ-
ity; and determination of EEG reactivity. EEG technicians 
assessed reactivity by application of a painful stimulus 
(usually a sternal rub) to determine if changes in fre-
quency or amplitude occurred. Previous experience with 
interpretation of EEGs in children with CM led us to 
characterize two types of reactivity, paradoxical or nor-
mal. EEG interpreters defined paradoxical reactivity as 
slowing in frequency or decrease in amplitude by more 
than 50% that occurred after application of a painful 
stimulus. Normal reactivity was defined as an increase in 
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frequency or amplitude by more than 50% that occurred 
after stimulation. An electrographic seizure was defined 
as a rhythmic repetitive spike-wave discharge with an 
electrical field that evolved in frequency, morphology, or 
amplitude over at least 10  s. Although several children 
had multiple EEGs performed during their hospital stay, 
only the first EEG obtained was used in this analysis as 
this would be the one most relevant for informing future 
clinical trials.
During hospitalization, clinical seizures were treated 
first with intravenous diazepam or intramuscular paral-
dehyde. If ictal phenomena were recurrent or prolonged, 
phenobarbital was added. Breakthrough seizures on phe-
nobarbital were treated by adding phenytoin. Clinical 
complications were treated as they developed. Continu-
ous EEG monitoring was not performed in either centre.
In the children who survived, outcome was determined 
at hospital discharge by parent interview and a neuro-
logical exam; examinations were performed by physi-
cians in Uganda and by a physician or clinical officer in 
Malawi. Clinical officers are paramedical professionals 
who undergo 3 years of technical training after second-
ary school. They are largely trained to use an algorithmic 
approach to patient care for conditions commonly seen 
in their region. They are not explicitly trained to conduct 
a detailed neurologic assessment.
Children whose parents stated they were not back to 
normal (new motor, cognitive, or behavioural abnormali-
ties), or children found to have new neurological signs 
on examination were classified as ‘alive with sequelae’. 
Those with normal neurological exams and whose par-
ents reported they were back to baseline were classified 
as ‘normal’. Across institutions, there were no further 
specific criteria to determine whether a child should be 
classified as normal versus alive with sequelae.
Statistical analysis
Demographic factors, clinical characteristics and dis-
charge outcomes of the study population were described 
using means (and standard deviations) or proportions. 
To evaluate differences between study site populations, 
comparisons were made in continuous and categorical 
EEG variables in Malawi and Uganda. Wilcoxon rank 
sum tests were used for comparisons of continuous data. 
Pearson’s Chi square tests were used for categorical data 
where all cell counts were ≥ 5; Fisher’s exact tests were 
used to analyse categorical data with cell counts  less 
than 5. Pooling data from Uganda and Malawi, univari-
ate analyses of continuous EEG variables (e.g. frequency, 
amplitude) in children of differing outcomes were com-
pared using Wilcoxon rank sum tests. Categorical EEG 
variables (e.g. asymmetry, reactivity, variability, pres-
ence or absence of electrographic seizures) in children of 
differing outcomes were compared using Pearson’s Chi 
square or Fisher’s exact test, as appropriate. A two-sided 
p < 0.05 was considered a statistically significant differ-
ence between groups.
Results
During the study period, 281 EEGs were performed 
and analysed, 122 from Uganda and 159 from Malawi. 
Tables  1 and 2 compare demographic, clinical, EEG and 
outcomes data between the two sites. The Malawian pop-
ulation was comprised only of retinopathy positive chil-
dren (versus 72.5% in Uganda) and were older (4.2 versus 
3.7  years; p = 0.046), had a higher HIV prevalence (9.0 
versus 2.8%; p = 0.042), and worse hyperlactataemia (7.4 
versus 5.2 mmol/L; p < 0.001) on admission than Ugandan 
children (Tables 1 and 2). In Uganda, 21 children (17.2%) 
died and 44 of the 100 survivors (44.0%) had neurologi-
cal sequelae at hospital discharge. (In one Ugandan survi-
vor, the presence or absence of neurological sequelae was 
unknown.) In Malawi, outcomes were better: 22 children 
(13.8%) died, and 11.3% (16 of the 137 survivors) had neu-
rological sequelae. There was no statistically significant 
difference in the mortality rates between Malawi and 
Uganda (p = 0.408). Rates of morbidity in survivors were 
significantly higher in Uganda than Malawi (p = 0.002). 
There were multiple statistically significant differ-
ences in admission EEGs when comparing Malawian and 
Ugandan children (Tables 1 and 2). Average voltage was 
lower and frequencies were slower in EEGs from Uganda 
compared to those from Malawi. EEG variability, sleep 
spindles, and vertex waves were significantly more com-
mon in Ugandan children, while EEGs from Malawian 
children were more likely to show asymmetry. There 
was no statistically significant difference in the propor-
tion of children with electrographic seizures in the two 
locations.
Tables  3 and 4 delineate the univariate analyses of 
pooled EEG findings associated with mortality. Death was 
associated with a lower average voltage (93.8 µV in survi-
vors compared to 69.9 µV in those who died, p = 0.0032), 
lower maximum voltage (210.6 µV in survivors compared 
to 171.1  µV in those who died, p = 0.0089), and slower 
dominant frequency (2.2  Hz in survivors compared to 
1.8  Hz in those who died, p = 0.0030). Focal slowing 
was associated with death (OR 2.93; 95% CI 1.77–7.30) 
and reactivity with survival (OR for death 0.37; 95% CI 
0.18–0.79).
A univariate analysis of pooled EEG findings associated 
with neurological morbidity in survivors revealed that a 
higher average voltage was associated with a normal neu-
rological outcome in survivors (101.9 µV in those with a 
normal outcome versus 70.1 µV in those with neurologi-
cal sequelae, p < 0.0001) (Tables 5 and 6). 
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Discussion
Despite the substantial noise of demographic and clinical 
heterogeneity between subjects in Malawi and Uganda as 
well as different EEG readers at each site, there is a clear 
signal that EEG findings on admission predict mortality 
and morbidity.
Admission EEG findings in children with CM from 
Uganda differ from those recorded in Malawi. Possi-
ble explanations for these differences may be specific to 
EEG (study technique, interpreter effect), intrinsic to the 
nature of any multi-centre study (studies obtained at dif-
ferent time points, different inclusion criteria) or could 
represent true differences between the Malawian and 
Ugandan paediatric CM populations.
EEG interpretation is a subjective process with no cur-
rently available tools for objective, reliable quantification 
of frequency, voltage, or any of the variables captured 
in this study. Although automated tools are available to 
aid interpretation, these are sensitive to artifact, creating 
both false positive and negative findings, when compared 
to human interpretation as the gold standard. Three 
interpreters reviewed the EEGs included here, which 
likely introduced variability into interpretations. Inter-
rater correlation between EEG variables in often modest 
[13], but relying on a single reader limits external gen-
eralizability [14]. The imperative to improve EEG inter-
rater reliability in the identification of triphasic waves, 
hypsarrhythmia and sleep architecture has recently 
resulted in efforts aimed at developing more standard-
ized terminology and/or additional reader training for 
the identification of specific findings [15–18]. If EEG is to 
be used for stratification and/or risk adjustment in multi-
site clinical trials of CM, improved standardization and/
Table 1 Comparison of clinical and EEG characteristics (continuous variables) between Malawian and Ugandan children 
with cerebral malaria (value ± SD) (denominators vary due to missing data)
Variable Uganda (N = 122) Malawi (N = 159) p value 
for difference
N Mean ± SD N Mean ± SD
Age (years) 122 3.75 ± 1.95 159 4.23 ± 2.27 0.0463
Glucose (mg/dL) 119 6.6 ± 3.4 159 7.1 ± 3.7 0.8200
Parasitemia (parasites/µL) (geometric 
mean)
116 33,288.5 148 33,239.2 0.9961
Lactate (mmol/L) 117 5.2 (4.0) 159 7.4 (4.1) < 0.0001
Blantyre Coma Score (n/N, %) 0.91
 0 9 (7.4) 12 (7.6)
 1 57 (46.7) 78 (49.1)
 2 56 (45.9) 69 (43.4)
Average voltage (µV) 117 65.77 ± 31.84 151 109.1 ± 55.17 < 0.0001
Maximum voltage (µV) 117 198.0 ± 73.16 152 209.9 ± 88.62 0.3866
Dominant frequency (Hz) 115 1.93 ± 0.73 148 2.34 ± 1.09 0.0132
Table 2 Comparison of clinical and EEG characteristics (categorical variables) between Malawian and Ugandan children 
with cerebral malaria (denominators vary due to missing data)
Variable Uganda (n/N, %) Malawi (n/N, %) p value 
for difference
Retinopathy positive 87/120 (72.5) 159/159 (100) –
HIV reactivity 3/109 (2.8) 13/144 (9.0) 0.0423
Variability (% with) 73/119 (61.3) 78/159 (49.1) 0.0418
Asymmetry (% with) 15/122 (12.3) 49/159 (30.8) 0.0002
Electrographic seizures (% with) 9/122 (7.4) 22/159 (13.8) 0.0867
Spindles (% with) 71/116 (61.2) 65/159 (40.9) 0.0009
Vertex sharp waves (% with) 56/118 (47.5) 39/159 (25.0) < 0.0001
Slowing location (% focal) 5/117 (4.2) 19/159 (11.9) 0.0240
Normal reactivity (% with increase in voltage and/or frequency with stimulus) 4/113 (3.5) 41/153 (26.8) < 0.0001
Paradoxical reactivity (% with decrease in voltage and/or frequency with 
stimulus)
40/113 (35.4) 27/153 (17.6)
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or development of validated sensitive and specific EEG 
interpretation software will be needed.
Despite these challenges, it is possible that the differ-
ences seen in admission EEGs between Malawian and 
Ugandan children represent intrinsic electrophysiological 
differences between populations. In terms of pathophysi-
ological insights, many of the EEG findings described 
in this study are seen in other aetiologies of paediatric 
coma. EEG findings in children with non-malarial central 
nervous system infections are considered non-specific 
as to aetiology (e.g. viral versus bacterial) and consist of 
generalized delta waves [19], as was seen in these study 
subjects. This pattern implies that large areas of subcor-
tical white matter are functionally abnormal [20]. Gen-
eralized slowing is seen more commonly in disorders 
primarily affecting white matter [21].
In a previous study of 201 children in coma in Italy, 26 
of 77 children with central nervous system bacterial or 
viral infections had convulsions, though the authors did 
not clarify whether seizure activity was clinical, electro-
graphic, or both [19]. Clinical seizures are very common 
in CM. In this study, non-continuous electrographic sei-
zures captured on a 30  min EEG were documented in 
only 11.0% of subjects and were not associated with mor-
tality or morbidity on pooled univariate analysis.
This study has several limitations. Continuous EEG 
monitoring was not performed, which likely led to a 
lack of sensitivity for ascertaining transient events. In 
paediatric traumatic brain injury, subclinical electro-
graphic seizures are common, and the combination of 
clinical and electrographic seizures may occur in up to 
77.3% of patients [14]. Studies of comatose children in 
paediatric intensive care units without restriction by 
coma aetiology reveal a 7% risk of subclinical electro-
graphic seizures [22], a proportion similar to that seen 
in this study’s subjects. It is not possible to know if con-
tinuous EEG sampling would have modified the asso-
ciations found here.
The analysis of EEG factors associated with neuro-
logical morbidity was complicated by a non-standard 
definition of this outcome across sites. For example, chil-
dren with mild ataxia that was resolving were coded as 
Table 3 Univariate analysis: Comparison of continuous clinical and EEG variables by outcome (mortality) (mean ± SD)
Country Clinical or EEG variable Alive (N = 101) Died (N = 21) p value
Uganda Age (years) 3.8 ± 1.9 3.6 ± 2.1 0.77
Glucose (mg/dL) 6.8 ± 3.3 5.6 ± 3.6 0.2622
Parasitemia (parasites/µL) [geometric mean 
(coefficient of variation)]
30,315.4 (21.9) 53,669.7 (6.5) 0.3463
Lactate (mmol/L) 4.9 ± 3.9 6.7 ± 4.1 0.0467
Average voltage (µV) 68.9 ± 31.9 50.5 ± 27.4 0.018
Maximum voltage (µV) 206.3 ± 71.0 158.0 ± 71.9 0.007
Dominant frequency (Hz) 2.0 ± 0.7 1.6 ± 0.9 0.02
Country Clinical or EEG variable Alive (N = 137) Died (N = 22) p value
Malawi Age (years) 4.3 ± 2.3 4.1 ± 2.2 0.70
Glucose (mg/dL) 7.1 ± 3.6 7.4 ± 4.1 0.8675
Parasitemia (parasites/µL) [geometric mean 
(coefficient of variation)]
31,053.5 (25.4) 50,153.1 (13.6) 0.4189
Lactate (mmol/L) 7.2 ± 4.1 8.6 ± 3.8 0.0827
Average voltage (µV) 112.2 ± 54.3 89.3 ± 58.2 0.08
Maximum voltage (µV) 213.8 ± 88.4 184.3 ± 88.2 0.17
Dominant frequency (Hz) 2.4 ± 1.1 1.9 ± 0.9 0.05
Country Clinical or EEG variable Alive (N = 238) Died (N = 43) p value
Uganda + Malawi Age (years) 4.0 ± 2.1 3.8 ± 2.1 0.3459
Glucose (mg/dL) 7.0 ± 3.5 6.5 ± 4.0 0.5049
Parasitemia (parasites/µL) [geometric mean 
(coefficient of variation)]
30,731.7 (23.5) 51,793.8 (9.0) 0.2168
Lactate (mmol/L) 6.2 ± 4.2 7.7 ± 4.0 0.0170
Average voltage (µV) 93.8 ± 50.8 69.9 ± 49.0 0.0032
Maximum voltage (µV) 210.6 ± 81.4 171.1 ± 80.6 0.0089
Dominant frequency (Hz) 2.2 ± 1.0 1.8 ± 0.9 0.0030
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“normal” in Malawi, but “abnormal” in Uganda. Future 
studies comparing EEG factors associated with neuro-
logical morbidity should standardize criteria to define 
neurosequelae. Children were classified as having neu-
rological morbidity at discharge. Since neurological 
sequelae at discharge may clear over time, or epilepsy 
Table 4 Comparison of categorical demographic and EEG variables by outcome (mortality) (OR, 95% CI)
a Odds of death of children having the EEG feature divided by the odds of death of children without the EEG feature
Country Clinical or EEG variable Children 
with variable who 
were alive
(N, %)
Children 
with variable 
who died
(N, %)
Odds  ratioa 95% 
confidence 
interval
p value
Uganda Total N (122) 101 21
Retinopathy positive 71 (70.3) 16 (73.2) 1.63 0.5, 5.3 0.41
HIV reactivity 3 (3.0) 0 (0.0)
Variability 62 (61.4) 11 (52.4) 0.64 0.25, 1.65 0.35
Asymmetry 13 (12.9) 2 (9.5) 0.71 0.15, 3.42 0.67
Electrographic seizures (present) 8 (7.9) 1 (4.8) 0.58 0.07, 4.9 0.62
Spindles (present) 60 (59.4) 11 (52.4) 0.64 0.25, 1.66 0.36
Vertex sharp waves 47 (46.5) 9 (42.9) 0.79 0.31, 2.07 0.64
Focal slowing 3 (2.9) 3 (14.3) 5.27 0.98, 28.3 0.052
Reactivity (normal + paradoxical) 40 (39.6) 4 (19.1) 0.306 0.09, 0.98 0.046
Normal reactivity (increase in voltage and/or 
frequency with stimulus)
37 (36.6) 3 (14.3) 1.02 0.09, 10.46 0.55
Paradoxical reactivity (decrease in voltage and/or 
frequency with stimulus)
3 (2.97) 1 (4.76) 0.25 0.07, 0.91 0.09
Malawi Total N (159) 137 22
Retinopathy positive 137 (100) 22 (100)
HIV reactivity 12 (9.7) 1 (5.0) 0.49 0.06, 4.0 0.5065
Variability 71 (51.8) 7 (31.8) 0.43 0.17, 1.13 0.087
Asymmetry 40 (29.2) 9 (40.9) 1.68 0.66, 4.23 0.27
Electrographic seizures present 16 (11.7) 6 (27.3) 2.84 0.97, 8.3 0.06
Spindles present 58 (42.3) 7 (31.8) 0.64 0.24, 1.66 0.35
Vertex sharp waves 37 (27.0) 2 (9.1) 0.27 0.06, 1.21 0.09
Focal slowing (focal versus gen) 14 (10.2) 5 (22.7) 2.58 0.83, 8.08 0.10
Reactivity (normal + paradoxical) 62 (45.3) 6 (27.3) 0.45 0.17, 1.2 0.12
Normal reactivity (increase in voltage and/or 
frequency with stimulus)
37 (27.0) 4 (18.2) 0.51 0.16, 1.63 0.77
Paradoxical reactivity (decrease in voltage and/or 
frequency with stimulus)
25 (18.2) 2 (9.1) 0.37 0.08, 1.75 0.42
Uganda + Malawi Total N (281) 238 43
Retinopathy positive 208 (87.4) 38 (88.4) 1.32 0.44,3.98 0.62
HIV reactivity 15 (6.7) 1 (3.5) 0.49 0.06, 3.91 0.5072
Variability 133 (55.9) 18 (41.9) 0.552 0.29,1.07 0.077
Asymmetry 53 (22.3) 11 (25.6) 1.20 0.57,2.54 0.634
Electrographic seizures present 24 (10.1) 7 (16.3) 1.73 0.69,4.32 0.24
Spindles present 118 (49.6) 18 (41.9) 0.696 0.36,1.34 0.28
Vertex sharp waves 84 (35.3) 11 (25.6) 0.614 0.29,1.28 0.19
Focal slowing 17 (7.1) 8 (18.6) 2.93 1.76,7.3 0.02
Reactivity (normal + paradoxical) 102 (42.9) 10 (23.3) 0.374 0.18,0.79 0.010
Reactivity (increase in voltage and/or frequency 
with stimulus)
40 (16.8) 5 (11.6) 0.477 0.17,1.31 0.79
Paradoxical reactivity (decrease in voltage and/or 
frequency with stimulus)
62 (26.1) 5 (11.6) 0.308 0.11,0.83 0.13
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may appear after a delay of months, misclassification 
may have occurred. Since post-CM epilepsy can develop 
months after hospitalization, this study could not iden-
tify acute EEG characteristics that are predictors of later 
developing epilepsy. Future studies should consider 
ascertainment of admission EEG factors associated with 
long-term neurological disability. In younger patients, 
post-CM developmental disabilities may be difficult to 
detect and only become clear as the patient ages, when 
the survivor’s developmental milestones diverge from 
those of their unaffected peer group. Identification of 
EEG changes in children at higher risk of a long-term 
adverse outcome may allow focus of limited resources 
(physiotherapy, palliative care) to those at highest risk.
Retinopathy negative children were not represented 
in Malawi, as children from this site were enrolled in a 
parent study whose primary interest was retinopathy 
positive CM. Since one-third of children with clinical CM 
are retinopathy negative, the population from Malawi 
may not be representative of the clinical spectrum of 
children with this illness.
Identification of EEG factors associated with death 
and long-term adverse neurological outcome may allow 
insights into whether these outcomes share a common 
pathophysiology. Since seizures are considered primar-
ily a gray matter-based abnormality, while slowing and 
decreased amplitudes are primary due abnormalities in 
the thalamo-cortical circuits (white matter based), it is 
possible that interventions successful in reducing rates of 
one outcome (mortality) may not lead to a change in the 
proportion of children with the other endpoint (e.g. an 
increase in the proportion of survivors with neurological 
disabilities).
Table 5 Univariate analysis: comparison of  continuous clinical and  EEG variables by  outcome (neurological morbidity 
in survivors) (mean ± SD)
Country Clinical or EEG variable Alive and normal (N = 56) Alive with sequelae 
(N = 44)
p value
Uganda Age (years) 3.8 ± 1.7 3.8 ± 2.2 0.5312
Glucose (mg/dL) 7.2 ± 3.3 6.4 ± 3.4 0.1376
Parasitemia (parasites/µL) [geometric mean 
(coefficient of variation)]
31,931.6 (23.3) 31,434.9 (18.7) 0.9755
Lactate (mmol/L) 4.6 ± 3.7 5.3 ± 4.2 0.4449
Average voltage (µV) 74.0 ± 32.1 63.6 ± 30.8 0.0723
Maximum voltage (µV) 213.8 ± 71.2 199.1 ± 70.3 0.3809
Dominant frequency (Hz) 2.0 ± 0.7 2.0 ± 0.6 0.9210
Country Clinical or EEG variable Alive and normal 
(N = 121)
Alive with sequelae 
(N = 16)
p value
Malawi Age (years) 4.3 ± 2.3 3.5 ± 1.9
Glucose (mg/dL) 6.9 ± 2.9 8.3 ± 7.0 0.6468
Parasitemia (parasites/µL) [geometric mean 
(coefficient of variation)]
28,148.2 (27.4) 73,486.0 (10.4) 0.1988
Lactate (mmol/L) 7.0 ± 4.0 8.4 ± 4.8 0.3023
Average voltage (µV) 114.5 ± 54.2 91.5 ± 52.6 0.2178
Maximum voltage (µV) 217.4 ± 86.3 180.0 ± 103.1 0.1185
Dominant frequency (Hz) 2.4 ± 1.1 2.1 ± 1.3 0.1550
Country Clinical or EEG variable Alive and normal 
(N = 177)
Alive with sequelae 
(N = 60)
p value
Uganda + Malawi Age (years) 4.2 ± 2.2 3.7 ± 2.1 0.0723
Glucose (mg/dL) 7.0 ± 3.0 6.9 ± 4.7 0.1999
Parasitemia (parasites/µL) [geometric mean 
(coefficient of variation)]
29,312.6 (25.57) 38,422.1 (16.66) 0.4876
Lactate (mmol/L) 6.3 ± 4.0 6.1 ± 4.5 0.5321
Average voltage (µV) 101.9 ± 51.9 70.1 ± 38.4 < 0.0001
Maximum voltage (µV) 216.3 ± 81.8 194.6 ± 78.5 0.0943
Dominant frequency (Hz) 2.3 ± 1.0 2.0 ± 0.8 0.0524
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Table 6 Comparison of  categorical demographic and  EEG variables by  outcome (neurological morbidity in  survivors) 
(OR, 95% CI)
Country Clinical or EEG variable Children with variable who 
were alive with sequelae
(N, %)
Children with variable who 
were alive without sequelae
(N, %)
Odds  ratioa 95% 
confidence 
interval
p value
Uganda Total N (101)
Retinopathy positive 32 (72.7) 38 (69.1) 1.19 0.49, 2.86 0.6930
HIV reactivity 3 (6.9) 0
Variability 28 (63.6) 34 (64.2) 0.98 0.43, 2.25 0.9581
Asymmetry 4 (9.1) 9 (16.1) 0.52 0.15, 1.83 0.3089
Electrographic seizures 
(present)
3 (6.8) 5 (8.9) 0.75 0.17, 3.31 0.7002
Spindles (present) 26 (61.9) 34 (64.2) 0.91 0.39, 2.10
Vertex sharp waves 22 (51.2) 25 (47.2) 1.17 0.52, 2.63 0.6972
Focal slowing 0 2 (3.8)
Reactivity (normal + paradoxi‑
cal)
15 (37.5) 25 (49.0) 0.62 0.27, 1.45 0.2730
Normal reactivity (increase in 
voltage and/or frequency 
with stimulus)
2 (5.0) 1 (1.9) 2.08 0.18, 24.40 0.4128
Paradoxical reactivity (decrease 
in voltage and/or frequency 
with stimulus)
13 (32.5) 24 (47.1) 0.56 0.24, 1.35 0.1895
Malawi Total N (137)
HIV reactivity 1 (7.1) 11 (10.0) 0.69 0.08, 5.81 0.7347
Variability 7 (43.8) 64 (52.9) 0.69 0.24, 1.98 0.4932
Asymmetry 7 (43.8) 33 (27.3) 2.07 0.72, 6.02 0.1797
Electrographic seizures present 6 (37.5) 10 (8.3) 6.7 2.0, 22.1 0.002
Spindles present 5 (31.3) 53 (43.8) 0.58 0.19, 1.78 0.3438
Vertex sharp waves 1 (6.3) 36 (29.8) 0.16 0.02, 1.24 0.0788
Focal slowing (focal versus gen) 4 (25.0) 10 (8.3) 3.7 1.01, 13.6 0.0491
Reactivity (normal + paradoxi‑
cal)
6 (37.5) 56 (48.3) 0.64 0.22, 1.89 0.4209
Normal Reactivity (increase in 
voltage and/or frequency 
with stimulus)
5 (31.3) 32 (27.6) 0.94 0.29, 2.98 0.3837
Paradoxical reactivity (decrease 
in voltage and/or frequency 
with stimulus)
1 (6.3) 24 (20.7) 0.25 0.03, 2.06 0.2025
Uganda + Malawi Total N (281)
Retinopathy positive 48 (80.0) 159 (90.3) 0.43 0.19, 0.96 0.0390
HIV reactivity 4 (7.0) 11 (6.6) 1.06 0.33, 3.48 0.9190
Variability 35 (58.3) 98 (56.3) 1.09 0.59, 1.97 0.7862
Asymmetry 11 (18.3) 42 (23.7) 0.72 0.34, 1.51 0.3875
Electrographic seizures present 9 (15.0) 15 (8.5) 1.91 0.79, 4.62 0.1529
Spindles present 31 (53.5) 87 (50.0) 1.15 0.63, 2.08 0.6493
Vertex sharp waves 23 (38.9) 61 (35.1) 1.18 0.64, 2.18 0.5875
Focal slowing 4 (6.8) 12 (6.9) 0.98 0.30, 3.17 0.9756
Reactivity (normal + paradoxi‑
cal)
21 (37.5) 81 (48.5) 0.64 0.34, 1.19 0.1543
Reactivity (increase in voltage 
and/or frequency with 
stimulus)
7 (12.5) 33 (19.8) 0.52 0.21, 1.29 0.2856
Paradoxical reactivity (decrease 
in voltage and/or frequency 
with stimulus)
14 (25.0) 48 (28.7) 0.72 0.35, 1.46 0.9846
a Odds of disability of children having the EEG feature divided by the odds of disability of children without the EEG feature
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Conclusions
In children with CM, death is associated with patterns 
on admission EEG. Findings increasing the risk of death 
include a lower average voltage, lower maximum voltage, 
slower dominant frequencies, focal slowing, and a lack 
of reactivity. For CM clinical trials aimed at decreasing 
mortality, EEG may be valuable for risk stratification and/
or subject selection.
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